<DOC>
	<DOCNO>NCT01890135</DOCNO>
	<brief_summary>Peripheral artery disease ( PAD ) major complication atherosclerosis blockages artery leg reduce blood flow one result problem term intermittent claudication ( IC ) . IC leg pain walk relieve rest IC frequent clinical manifestation PAD effect million Americans . The number patient , health care cost , PAD increase prevalence PAD associate advance age , diabetes , smoke . Zibotentan ( ZD4054 ) endothelin receptor A ( ETA ) blocker undergone extensive human test show safe several patient population . There ample evidence suggest ETA blocker could improve blood flow legs patient PAD . In study fund National Institute Health , investigator test ability medication allow well blood flow leg patient PAD . In patient IC , investigator test ability ZD4054 improve leg blood flow use non-invasive imaging technique . In parallel study test ability patient leg pain walk feel well .</brief_summary>
	<brief_title>Zibotentan , Endothelin Receptor Antagonist , Patients With Intermittent Claudication</brief_title>
	<detailed_description>Peripheral artery disease ( PAD ) major complication atherosclerosis affect &gt; 8 million people United States alone . Intermittent claudication ( IC ) , define leg pain walk relieve rest , frequent clinical manifestation PAD . In proposal funded National Institute Health ( NIH ) National Center Advancing TRanslational Sciences ( NCATS ) investigator pose test `` reuse '' zibotentan ( ZD4054 , Asta-Zeneca compound ) , orally active , endothelin receptor A ( ETA ) antagonist patient IC . The study seek confirm safety tolerability 10mg ZD4054 patient intermittent claudication ( Rutherford II III ) , parallel , establish capacity ZD4054 change calf muscle perfusion , assess contrast-enhanced magnetic resonance imaging , functional treadmill performance , quality life indicator . The study 1:1 randomize , double-blind , placebo-controlled trial 44 subject intermittent claudication randomization stratify base entry calf muscle perfusion . The investigator use magnetic resonance image quantify change blood flow ischemic limb baseline week 12 randomize drug vs. placebo . Based prior experience know tolerability ZD4054 , experience investigative team mechanistically appropriate end-point measure part NIH fund project , investigator proceed directly Phase II trial . The primary endpoint study change absolute perfusion index calf muscle baseline follow-up , 12 week 10 mg dose placebo . Additional outcome measure : ) ability patient PAD tolerate 10 mg dose ZD4054 vs. placebo ; b ) freedom unexpected serious adverse event ; c ) change peak walk time baseline 12 week 10 mg ZD4054 placebo group ; ) change ankle-brachial blood pressure index ( ABI ) baseline 12 week 10 mg ZD4054 placebo group , ; ) change quality life measure 10 mg ZD4054 placebo group .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Age &gt; 40 year . Patients le 40 year age could well form `` thromboangitis obliterans '' often call Berger 's Disease investigator wish enroll subject atherosclerotic vascular disease . Currently take standard medication part `` good medical care '' patient PAD include antiplatlet agent , angiotensinconverting enzyme inhibitor receptor blocker , betablockers indicate ischemic heart disease , cholesterol lower therapy ; unless document contraindication therapy exist . Those patient therapy refer back suggestion add reapproached enrollment later date . Exercise induced thigh , calf , buttock pain absence Rutherford Class IV , V , VI.3 A rest ABI &lt; 0.9 &gt; 0.4 presence superficial femoral artery stenosis ( 70 % great ) disease knee disease significant stenosis least one runoff vessel . Absence critical inflow ( iliac common femoral ) disease . The profunda femoral artery major source collateral blood vessel . The investigator initial approach try enroll homogenous patient population possible allow u focus primary endpoint study ( change muscle perfusion ischemic limb time ) . Ability undergo magnetic resonance image provide inform write consent . Serious know concomitant disease life expectancy le one year Prior amputation history critical limb ischemia Creatinine clearance ( CrCl ) &gt; 45 permit safe administration gadolinium contrast agent . Recent myocardial infarction , unstable angina , stroke transient ischemic attack within 3 month . American Heart Association Class III IV congestive heart failure know leave ventricular ejection fraction le 40 % . Known history anemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>randomize</keyword>
	<keyword>double blind</keyword>
	<keyword>blood flow</keyword>
	<keyword>muscle perfusion</keyword>
	<keyword>safety</keyword>
</DOC>